SEC Comment Letter for Lineage Cell Therapeutics, (LCTX) — Mar 16, 2021
Lineage Cell Therapeutics, Inc.
Date: March 16, 2021 · CIK: 0000876343 · Accession: 0000000000-21-003134
AI Filing Summary & Sentiment
File numbers found in text: 333-254155
Letter
United States securities and exchange commission logo March 16, 2021 Brian M. Culley Chief Executive Officer Lineage Cell Therapeutics, Inc. 2173 Salk Avenue, Suite 200 Carlsbad, CA 92008 Re:Lineage Cell Therapeutics, Inc. Registration Statement on Form S-3 Filed March 11, 2021 File No. 333-254155 Dear Mr. Culley: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jordan Metoyer at 202-551-6001 or Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Steven M. Przesmicki, Esq.
Show Raw Text
United States securities and exchange commission logo
March 16, 2021
Brian M. Culley
Chief Executive Officer
Lineage Cell Therapeutics, Inc.
2173 Salk Avenue, Suite 200
Carlsbad, CA 92008
Re:Lineage Cell Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 11, 2021
File No. 333-254155
Dear Mr. Culley:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jordan Metoyer at 202-551-6001 or Tim Buchmiller at 202-551-3635 with
any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Steven M. Przesmicki, Esq.